What Is the Rate of Stuttering Recovery?

Patient Presentation
A 6-year-old female came to clinic with sore throat and fever for 1 day. She had had 3 days of rhinorrhea. She was drinking and urinating well and denied other pain, rash, nausea or emesis. The past medical history revealed a history of stuttering that began around age 3 and started causing social problems when she entered kindergarten as peers starting to make fun of her. She had started private speech therapy about 1 year before the visit.

The pertinent physical exam showed a slightly tired appearing female with a temperature of 38.2°C, respiratory rate of 20/minute, and heart rate of 106/minute. HEENT revealed a reddened pharynx with white patches on her tonsils bilaterally. There was small anterior cervical adenopathy. The rest of her examination was normal. The laboratory evaluation of a rapid strep test was positive. The diagnosis of strep throat was made and penicillin was prescribed. During the visit, the pediatrician had remarked to the mother how much she thought the child’s stuttering had improved. The mother responded that it had “really improved” and they were probably going to stop the therapy soon.

Stuttering is defined as to utter with involuntary repetition of sounds. This commonly occurs in young children especially of initial sounds (Li-li-li-like he can’t do that!) but it can be whole word repetition (Like-like-like he can’t do that!). Stuttering as a normal utterance markedly decreases by age 6, so by age 7 if the child has stuttering the child should be evaluated by a professional speech and language pathologist (SLP). Indications for referral to a SLP for stuttering and other problems can be found here.

A recent review of stuttering epidemiology found:

  • Initiation of stuttering occurs usually before age 5, most often around 3 years of age
  • Females are more affected than males
  • Higher socio-economic status has been shown to occur in some studies, but there are methodological problems with some of the studies
  • Overall life incidence of 7-8%, and prevalence of <1%
  • Genetic studies have found that ~70% of stuttering may be due to genetics and have found a variety of candidate genes on numerous chromosomes depending on the type of study.

Treatment for stuttering in the past has tried a variety of pharmacological treatments with conflicting results as to efficacy and potentially serious negative side effects. Behavioral interventions with SLPs are the mainstay of treatment for patients and families. Behavioral treatment is defined as “…interventions that involve a change in speech behavior through (a) the direct modification of the person stuttering, (b) operant procedures, or (c) in integration of both approaches.” Some examples of behavioral treatments includes:

  • Speech motor training where language is broken into smaller parts and relearned through several methods. These parts are then used in word and sentence formation that becomes increasing complex over time
  • Delayed auditory feedback where the patient hears their own speech but with a slight delay which hopefully helps them to slow their speech rate. The feedback delay is then decreased over time to no delay, with hopefully retained normal speech rate over time.
  • Gradual increase in speech complexity is where one word fluency is achieved with a slow rate of speech, and gradually the words are combined into longer and more complex sentences.
  • Extended utterance length is similar to gradual increase in speech complexity but fluency is initially at the syllable level
  • Smooth speech is based on prolonged speech treatment where fluency is improved by smooth initiation of words and transitions between words

Many studies have evaluated the % of syllables stuttered as an efficacy measure. In a recent systematic review and meta-analysis, behavioral interventions (N=9 of 4 different behavioral treatments) decreased syllables stuttered by 1 standard deviation usually which was clinically significant for the patients. Five of the studies evaluated the Lidcombe Program developed at the University of Sydney and found it to provide consistent improvement. In this program where the premise is that the parent provides therapy to the child on a daily basis in their own home, the patient and family sees a SLP weekly to provide direct therapy. The SLP also works with the parent in particular to provide feedback to their child daily in their own home and evaluate the stuttering daily. The information is reviewed at the next weekly session. This continues for approximately 1 year until particular ends points are reached. The direct SLP sessions become less frequent but still occur to “maintain” the previous level of improvement, and hopefully have continued improvement.

Learning Point
Rates of stuttering recovery are very high and newer data may indicate even better recovery. Traditionally 85% stuttering recovery has been cited, but newer data cites recovery as closer to 90% and maybe even higher.

Questions for Further Discussion
1. What type of speech and language therapy is available in your location?
2. What are indications for a hearing test?

Related Cases

To Learn More
To view pediatric review articles on this topic from the past year check PubMed.

Evidence-based medicine information on this topic can be found at SearchingPediatrics.com, the National Guideline Clearinghouse and the Cochrane Database of Systematic Reviews.

Information prescriptions for patients can be found at MedlinePlus for these topics: Stuttering and Speech and Communication Disorders.

To view current news articles on this topic check Google News.

To view images related to this topic check Google Images.

To view videos related to this topic check YouTube Videos.

University of Sydney. Lidcombe Program. Available from the Internet at http://sydney.edu.au/health-sciences/asrc/clinic/parents/lidcombe.shtml (rev. 09/24/12, cited 9/21/15)

Ward D. Risk factors and stuttering: evaluating the evidence for clinicians. J Fluency Disord. 2013 Jun;38(2):134-40.

Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord. 2013 Jun;38(2):66-87.

Nye C, Vanryckeghem M, Schwartz JB, Herder C, Turner HM 3rd, Howard C. Behavioral stuttering interventions for children and adolescents: a systematic review and meta-analysis. J Speech Lang Hear Res. 2013 Jun;56(3):921-32.

Donna M. D’Alessandro, MD
Professor of Pediatrics, University of Iowa Children’s Hospital

What Are the Clinical Presentation of Charcot-Marie-Tooth Disease?

Patient Presentation
A 2-year-old male came to clinic for his health supervision. The mother was concerned that he was somewhat clumsy. “It’s always seems like he will just fall down for no good reason. He has bruises on his shins that I’ve noticed too,” she complained. “He’s pretty active and keeps up with his older sister and other kids though. Nothing stops him” she related. The past medical history showed a full-term infant without any pre- or peri-natal problems. His development had been tracking and by developmental screening questionnaire during the office visit was also on track. The review of systems was also normal. When reviewing the family history the mother became serious. “I wanted to bring up the falling down, because at our family reunion this summer I found out that one of my cousin’s sons has just been diagnosed with Charcot-Marie-Tooth disease. My cousin’s wife wasn’t worried about it, so I didn’t think anything at the time, but then I looked it up on the Internet and found out there can be real problems that get worse. It’s really bothering me and I’m wondering if we should test him for it?” she asked. The mother said that that the affected child was diagnosed at age 8 after he was noticed to have problems with writing that the teachers complained about. The mother said, “The boy’s father is my first cousin on my father’s side. The boy’s mother married into our family and said at the reunion that she has no problems.” The boy’s siblings are well also. The patient’s sister was a healthy 4 year old, and there were no neurological diseases in either side of the family that the mother was aware of or early infant deaths.

The pertinent physical exam showed a well-appearing male with normal vital signs and growth parameters. He scribbled on a chalkboard appropriately in the room, walked and climbed up onto the examination table and chair from the floor without difficulties. His extremities showed a few scattered bruises on his shins in various stage of healing. Cranial nerves III-XI were intact. He had good muscle bulk, strength, tone and normal deep tendon reflexes. No clonus or muscle wasting was noted. He was able to get up from a seated position on the floor without difficulties (i.e. no Gower sign) and appeared to have a normal gait for age walking and running. The rest of his examination was negative.

The diagnosis of a healthy 2 year old was made, but with a new diagnosis of Charcot-Marie-Tooth disease in a second cousin. The pediatrician said, “By what you’re telling me and his normal physical exam he looks like a healthy normal boy to me at this time. I haven’t read about Charcot-Marie-Tooth for quite a while so I would need to look that up to be able to know if your children should be tested. Do you think that your cousin would be willing to share more information about his son? Having the exact name, and what the boy’s doctors have told the parents about who else in the family might need to be tested would be really helpful.” The mother said she would talk with her cousin. A few weeks later, the patient’s sister returned for her own health supervision visit. The mother relayed that the affected boy had been diagnosed with a X-linked form of Charcot-Marie-Tooth and therefore the boy’s mother’s family was most likely affected and were being informed. “My cousin said that at this time the father’s family, like us, doesn’t need to be evaluated but I’m going to keep in touch with my cousin about this. They also said that the boy should do very well over time but will probably have more problems with handwriting and doing other things like tying shoes. I’m just glad that he will be OK,” the mother explained.

Charcot-Marie-Tooth disease (CMT) or hereditary motor and sensory neuropathy, is the most common cause of inherited neuropathies affecting 10-82:100,000 individuals. CMT comprises a heterogeneous group of peripheral, chronic inherited neuropathies that affects both the motor and sensory neurons and which have different genetic causations. Charcot and Marie were both French neurologists and Tooth was a British neurologist who described distal muscle wasting in 1886. Dejerine and Sottas reported the infantile form in 1893 which bears their name for this more severe clinical subtype. CMT classification is advancing as new testing becomes available but currently is classified as:

  • CMT1
    • Most common variant of CMT (70%)
    • Autosomal dominant
    • Has different subgroups but the most common subgroup is CMT1A which codes for a peripheral nerve protein 22 on chromosome 17
    • Identified most often with classic clinical presentation (see below)
    • Has slow nerve conduction and demyelination
  • CMT2
    • Autosomal dominant
    • Clinical indistinguishable from CMT except for nerve conduction studies
    • Has near normal nerve conduction and no demyelination
  • CMT3 or Dejerine-Sottas disease
    • Autosomal dominant or recessive
    • Has hypertrophy of nerve fibers often described as an “onion-bulb” in appearance on biopsy
    • This is the classic infantile onset clinical presentation (see below)
    • Has very slow nerve conduction times and demyeliation
  • CMT4
    • Autosomal recessive
    • Rare with distinct phenotypes
  • CMTX
    • Second most common form of CMT (10%)
    • X-linked dominant
    • More severe in males than females. Females may have few symptoms.
    • Have slowed nerve conduction times

Learning Point
Clinical phenotypes of CMT are often describe as classic and then age based.

  • The classic phenotype is being able to walk on time around 12 to 15 months of age but with the development of weakness or sensory loss over the next 20 years. Symptoms slow after that time but patients usually require few ambulatory aids.
    This is commonly found for CMT1A and men with CMTX.

  • Infantile onset shows patients that do not begin walking on time. There are severely affected and likely to require ambulatory aids by the age of 20.
    Examples are some patients with CMT3 and CMT1.

  • Adult onset where patients may have no symptoms until middle age. This is common in some variations of CMT1 and women with CMTX.

“The neuropathy of CMT is length dependent, which means that the longest nerves in the body are affected first and most severely.” Lower extremities are usually affected before the upper extremities.

Symptoms vary greatly by individual and subtypes. Patients often come to attention because of difficulties in walking or running including toe walking, tripping or falling, or just general clumsiness for gross motor movement. There also may be foot (pes cavus or hammar toes) or ankle injuries because of the muscle weakness. Upper extremity symptoms may not come to attention until the child has to perform fine motor movements such as tying shoes, dressing or writing. Infants may have hypotonia, hip dysplasia and feeding problems.

On physical examination muscle weakness and wasting can be subtle or obvious. Wasting is often seen in the hands. Sensory nerve abnormalities are often less prominent but decreaseed joint position and vibration tend to be more affected than temperature or pin prick sensations. Gait abnormalities are common depending on severity and individual compensation.

After diagnosis which often requires neurology and genetic evaluations, patients and families may need treatment. Treatment has to be individualized to preserve quality of life, particularly mobility, being the most important. Multidisciplinary treatment including physical therapy (focusing on range of motion, strengthening and balance) occupational therapy (improving activities of daily living and handwriting) and orthopedic surgery (to maintain ambulation and decrease pain associated with structural and functional problems) are important for families.

Questions for Further Discussion
1. What are causes of peripheral neuropathy? See a Review here
2. What are distinguishing features between a neuropathy and a myopathy?
3. What data do you use to determine if a family member needs screening or diagnostic testing for a potential disease?
4. What are the ethical issues of genetic testing for minor children?

Related Cases

To Learn More
To view pediatric review articles on this topic from the past year check PubMed.

Evidence-based medicine information on this topic can be found at SearchingPediatrics.com, the National Guideline Clearinghouse and the Cochrane Database of Systematic Reviews.

Information prescriptions for patients can be found at MedlinePlus for this topic: Charcot-Marie-Tooth Disease

To view current news articles on this topic check Google News.

To view images related to this topic check Google Images.

To view videos related to this topic check YouTube Videos.

Yagerman SE, Cross MB, Green DW, Scher DM. Pediatric orthopedic conditions in Charcot-Marie-Tooth disease: a literature review. Curr Opin Pediatr. 2012 Feb;24(1):50-6.

Patzko A, Shy ME. Charcot-Marie-Tooth disease and related genetic neuropathies. Continuum (Minneap Minn). 2012 Feb;18(1):39-59.

Jani-Acsadi A, Ounpuu S, Pierz K, Acsadi G. Pediatric Charcot-Marie-Tooth disease. Pediatr Clin North Am. 2015 Jun;62(3):767-86.

Donna M. D’Alessandro, MD
Professor of Pediatrics, University of Iowa Children’s Hospital

What Are Potential Treatments for Irritable Bowel Syndrome?

Patient Presentation
An 11-year-old female came to clinic for evaluation of recurrent abdominal pain. She had been seen twice in the emergency room and once in the outpatient clinic for similar problems over the past two months. The episodes occurred at least once a week and would cause her to not want to go to her music lessons and she would lie down for a while. Occasionally she would take acetaminophen for the pain. She described periumbilical pain without radiation and which improved with defecation. She said that her stools were “looser” but denied any blood or mucous. The episodes were not increasing in frequency or intensity and never occurred at night. She denied any bloating, flatulance or emesis. She ate a normal, mixed diet and the pain did not appear related to meals. They had been traveling in the region where she lived for musical recitals which she enjoyed but had been drinking from municipal water supplies. She also has not been around non-domestic animals. She had not had menarche. She had not been around anyone with gastrointestinal complaints nor had taken any medications other than the acetaminophen. The past medical history revealed that she was a high achieving individual both in the classroom and in regional music competitions. The family history is remarkable for high achieving parents. The mother related that she has always had some “stomach trouble” that she watched her diet for, especially her fiber intake. There was no gastrointestinal or rheumatological diseases in the family. There was a maternal uncle with basal cell skin cancer that was treated with excision. The review of systems was negative including no weight, skin, urinary, or vision changes.

The pertinent physical exam showed a healthy female who had gained 1.5 kilograms since her well child visit several months ago and who had gained 0.5 kg since the onset of her pain. Her weight was 25% and height was 50%. Her abdominal examination showed normal bowel sounds, with no masses or splenomegaly. She had no pain with palpation and rectal examination had normal tone without masses palpable. Genitourinary examination showed a normal female with patent vaginal opening. The work-up included a complete blood count, erythrocyte sedimentation rate, electrolytes, urinalysis and stool guiac which were all negative. Because of parental concerns and the regional travel, stool cultures were also negative eventually.

The diagnosis of irritable bowel syndrome was made. The family was counseled about the etiology and natural history with an emphasis that the patient was having real pain yet there is not anything seriously wrong with her gastrointestinal tract. The family was instructed to keep consistent habits for sleep, eating, school and other activities. They were asked to keep a symptom diary. The mother said that she would especially be sure that the child had adequate fiber in her diet. “I know that this helps me, so I hope it will help her,” the mother stated. The patient’s clinical course at followup 6 weeks later showed marked improvement with only 2 episodes of pain. The diary also showed that the pain seemed to be around when she was doing more musical performances, so the family said they were try to be aware and supportive of the patient around those times.

Abdominal pain is a common problem for children and a review can be found here.here. Functional gastrointestinal diseases are one of the most common problems not only in children but throughout the lifespan and a review can be found here.

Irritable bowel syndrome (IBS) is the most common functional gastrointestinal diseases with 10 to 15% of children suffering from IBS. The cause is unknown but it is considered a brain-gut disorder. “It is postulated that the state of disregulation exists/occurs within the enteric and the central nervous systems in patients with IBS and this results in alteration in sensation, motility, and possibly, immune system dysfunction.” It is most likely due to complex interaction between hereditary and environmental factors.

The Rome III criteria for IBS is:

  • Irritable Bowel Syndrome
    • Criteria fulfilled at least once per week for at least 2 months prior to diagnosis
    • Must include both of the following:
      • Abdominal discomfort (meaning an uncomfortable sensation not described as pain) or pain associated with two or more of the following at least 25% of the time:
        • Improvement with defecation
        • Onset associated with a change in frequency of stool
        • Onset associated with a change in form (appearance) of stool
      • No evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the subject’s symptoms

Classically the change in bowel frequency or consistency is associated with periumbilical abdominal pain that is relieved by defecation. Symptoms will also worsen during periods of emotional distress. There are 3 non-mutually exclusive subtypes. IBSC which has constipation as a predominant symptom. IBSD which has diarrhea as a predominant symptom. And IBSA which alternates between constipation and diarrhea. Patients may have one predominant subtype and overtime have another.

A thorough history and physical examination is important to look for “red flags” possibly indicating organic disease which include:

  • Growth problems and unintentional weight loss
  • Significant GI complaints including emesis, diarrhea and blood in the stool
  • Pain that is not periumbilical (or radiates) or pain at night
  • Systemic symptoms – fever, rash, joint pain, urinary symptoms, apthous ulcers
  • Family history of gastrointestinal organic disease – inflammatory bowel disease, ulcer, celiac disease
  • Abnormal laboratory testing – elevated inflammatory markers, anemia, etc.

Basic laboratory testing are also important in excluding more serious disease and can include a basic metabolic panel, complete blood count, C-reactive protein or erythrocyte sedimentation rate, urinalysis and urine culture and stool guaiac. Additional testing may be indicated based on the patient’s history such as stool for ova and parasites with a history of travel or animal exposure, stool C. difficile after antibiotics or breath hydrogen testing for possible malabsorption.

Despite best clinical efforts, some patients with IBS will eventually be diagnosed with a more serious alternative diagnosis. A study of adults 18 to 75 years old diagnosed with IBS found that there was a small increased incidence of Crohn’s disease, inflammatory bowel disease and colorectal cancer. The greatest risk was in the first 6 months of diagnosis and the authors believe that this is due to timing of the diagnostic evaluation for the patients. This finding was true even for young adults in the 18 to 29 year range.

Learning Point
After a thorough history, physical examination and laboratory evaluation excludes evidence of organic causes or other functional abdominal pain etiologies, the diagnosis of IBS can be made based on the criteria above.
The most important step in treatment of IBS is explaining to the family and the child the diagnosis, the natural history and providing reassurance that there is no underlying serious pathology. This often provides adequate treatment for the child and family. However some children have more severe symptoms and therefore need further intervention.
Dietary interventions are one of the most common and generally accepted treatments for families. There is some evidence that fiber supplementation help patients with IBSC subtype disease. A low fiber diet could be beneficial for those with IBSD. Use of partially hydrolyzed guar gum may help patients with IBSA.
Probiotics have been used for adult patients with IBS. They are considered safe to use and may be helpful for patients whose symptoms were initiated as the result of an infectious etiology such as gastroenteritis.
Medications generally show weak evidence of benefit. Peppermint oil and trimebutine maleate can be helpful for some children with spasmotic pain. Antibiotics are usually not recommended but can be useful if bacterial overgrowth is suspected. The antidepressant amitriptyline is effective in adults.
Hypnotherapy and yoga have also shown some beneficial effects in children. Cognitive behavioral therapy is often prescribed but evidence is not strong to support it.

Questions for Further Discussion
1. What are the key signs and symptoms of Crohn’s disease and inflammatory bowel disease?
2. What are other functional abdominal pain syndromes?

Related Cases

To Learn More
To view pediatric review articles on this topic from the past year check PubMed.

Evidence-based medicine information on this topic can be found at SearchingPediatrics.com, the National Guideline Clearinghouse and the Cochrane Database of Systematic Reviews.

Information prescriptions for patients can be found at MedlinePlus for these topics: Irritable Bowel Syndrome and Abdominal Pain.

To view current news articles on this topic check Google News.

To view images related to this topic check Google Images.

To view videos related to this topic check YouTube Videos.

Sandhu BK, Paul SP. Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment.
World J Gastroenterol. 2014 May 28;20(20):6013-23.

Paul SP, Barnard P, Bigwood C, Candy DC. Challenges in management of irritable bowel syndrome in children.
Indian Pediatr. 2013 Dec;50(12):1137-43.

Canavan C, Card T, West J. The incidence of other gastroenterological disease following diagnosis of irritable bowel syndrome in the UK: a cohort study.
PLoS One. 2014 Sep 19;9(9):e106478.

Donna M. D’Alessandro, MD
Professor of Pediatrics, University of Iowa Children’s Hospital

What is the Epidemiology of Adolescent E-Cigarette Use?

Patient Presentation
A 14-year-old male came to clinic for a sports physical. He played soccer and baseball and denied any significant sports injuries or concussions. He was doing well in school and had several friends that he liked to play sports or video games with. During the interview, he said that he had tried smoking with an e-cigarette that an older student had given him. He said that it was chocolate flavored and tasted “okay” but he really didn’t like it much and hasn’t tried it since. He denied any other tobacco, drugs or alcohol use. The past medical history showed a broken arm in the 2nd grade. The social history revealed maternal grandparents that smoked.

The pertinent physical exam showed a well appearing male with normal vital signs and growth parameters in the 25-75%. His physical examination had no focal findings. The diagnosis of a healthy male with what appears to be low risk, risk-taking was made. The physician reiterated that tobacco use in all forms was not healthy. “Although using e-cigarettes isn’t illegal in our state, buying them is. Plus your soccer and baseball teams have rules against using them and sports are important to you. You probably don’t want to get kicked off the team, so I would try to stay away from it if possible,” the physician said. They then discussed some ways that the teen could say no to substances if he was in a similar situation, and brainstormed who he might call to pick him up from a friend’s house or party if he wanted to get out of the situation.

Electronic cigarettes, e-cigarettes or electronic nicotine delivery devices (ENDS) are battery-powered devices that vaporize nicotine or non-nicotine containing solutions by a heating element. They were originally introduced into the global market around 2004 and in the United States market in 2007. Their use is commonly called vaping. The vaporized solutions are called e-liquids which usually contain propylene glycol, glycerin, water, nicotine, and flavorings, but variations without different components are sold as well. The devices can also be modified to vaporize other combustible materials such as oils, wax, and dried materials such as tobacco or cannibas.

The potential risks of e-cigarettes are not fully elucidated to date, but potential risks include:

  • Nicotine addiction
  • Inhalation, ingestion, or absorption of harmful chemicals including various carcinogens, nicotine, formaldehyde and acetylaldehyde
  • Potential use of other drugs and/or alcohol
  • Burns from the heating elements
  • Long-term effects that are currently unknown

Potential benefits of e-cigarettes could be decreased risks compared to combustible cigarettes or for smoking cessation, but again data is unproven to date.

Countries worldwide are recognizing the unknown but potential effects of e-cigarettes and are increasing their regulation. The United States Food and Drug Administration is currently seeking to extend its legal authority to regulate e-cigarettes in addition to the numerous tobacco products that it already oversees and regulates. Additionally, US state legislatures and local municipalities may or may not have laws that regulate e-cigarette purchase and use, particularly for minors. The American Academy of Pediatrics recommends children not be exposed or use any tobacco products in any form and the minimum age to purchase products be consistent across the US at age 21 years.

As with all potentially hazardous materials, e-cigarettes and liquid nicotine should be kept locked up and out of the reach of children. E-cigarette users should follow the package label for appropriate disposal.

Learning Point

The use of e-cigarettes by minors in the United States is rapidly increasing. Many data sources cite ~20% use of e-cigarettes by teens with a current trend that is increasing, and a stable or decreasing trends (~10-15%) for cigarette use. A study of high school students in Hawaii with data collected in 2013 found that 17% used e-cigarettes, 12% had dual use of e-cigarette’s and conventional combustible cigarettes (cigarettes), and only 3% used combustible cigarettes. A study of high school students in California with data collected in 2014 found 24% used e-cigarettes, 3.2% reported dual use, and 18.7% used cigarettes. The National Youth Tobacco Survey found an increase in e-cigarette use from 2011 to 2014 (2011 = 1.5% and 2014 = 13.4%). Cigarette and e-cigarette use has been strongly associated but during the same time, there has been a decrease in cigarette use among teens (2011 = 15.8% and 2014 = 9.2%). A study of high school students in Connecticut with data collected in 2014 found 18% e-cigarette usage. A significent number of the teens had also used the devices to vaporize cannibas variants including hash oil (15-23%), wax fused with the cannibas’s active ingredient (10-15%) or used dry cannabis leaves (20-29%).

Questions for Further Discussion
1. What are the acute affects of nicotine overdose?
2. What are risk factors for use of e-cigarettes and other tobacco products?
3. How much do e-cigarettes devices and e-liquid cost?

Related Cases

To Learn More
To view pediatric review articles on this topic from the past year check PubMed.

Evidence-based medicine information on this topic can be found at SearchingPediatrics.com, the National Guideline Clearinghouse and the Cochrane Database of Systematic Reviews.

Information prescriptions for patients can be found at MedlinePlus for these topics: Smoking and Youth and Smoking.

To view current news articles on this topic check Google News.

To view images related to this topic check Google Images.

To view videos related to this topic check YouTube Videos.

Wills TA, Knight R, Williams RJ, Pagano I, Sargent JD. Risk factors for exclusive e-cigarette use and dual e-cigarette use and tobacco use in adolescents. Pediatrics. 2015 Jan;135(1):e43-51.

Pbert L, Farber H, Horn K, Lando HA, Muramoto M, O’Loughlin J, Tanski S, Wellman RJ, Winickoff JP, Klein JD; American Academy of Pediatrics, Julius B. Richmond Center of Excellence Tobacco Consortium. State-of-the-art office-based interventions to eliminate youth tobacco use: the past decade. Pediatrics. 2015 Apr;135(4):734-47.

Barrington-Trimis JL, Berhane K, Unger JB, Cruz TB, Huh J, Leventhal AM, et.al. Psychosocial Factors Associated With Adolescent Electronic Cigarette and Cigarette Use. Pediatrics. 2015 Aug;136(2):308-17.

Morean ME, Kong G, Camenga DR, Cavallo DA, Krishnan-Sarin S. High School Students’ Use of Electronic Cigarettes to Vaporize Cannabis. Pediatrics. 2015 Sep 7. pii: peds.2015-1727.

American Non Smokers Rights Foundation. States and Municipalities with Laws Regulating Use of Electronic Cigarettes. Available from the Internet at http://www.no-smoke.org/pdf/ecigslaws.pdf (rev. 6/1/15, cited 9/16/15).

National Convention of State Legislatures. Alternative Nicotine Products, Electronic Cigarettes. Available from the Internet at http://www.ncsl.org/research/health/alternative-nicotine-products-e-cigarettes.aspx (rev. 8/11/15, cited 9/16/15).

American Academy of Pediatrics. AAP Statement on New E-Cigarette Poisoning Data, Need for Government Action. Available from the Internet at https://www.aap.org/en-us/about-the-aap/aap-press-room/pages/EcigarettePoisoning.aspx (rev. no date, cited 9/16/15).

American Academy of Pediatrics. Electronic Nicotine Delivery Systems. Available from the Internet at http://www2.aap.org/richmondcenter/ENDS.html (rev. no date, cited 9/16/15).

American Academy of Pediatrics. Clinical Practice Policy to Protect Children From Tobacco, Nicotine,and Tobacco Smoke. Available from the Internet at: http://pediatrics.aappublications.org/content/early/2015/10/21/peds.2015-3108.full.pdf+html (rev. 10/26/2015, cited 10/26/2015).


Donna M. D’Alessandro, MD
Professor of Pediatrics, University of Iowa Children’s Hospital